Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR101 PET/CT Imaging in Healthy Males and Suspected Prostate Cancer
NCT06472531Phase 2Completed
- Sponsor
- Yunhe Pharmaceutical
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of INR101 in prostate cancer (PCa), sponsored by Yunhe Pharmaceutical. Primary endpoints: Incidence of adverse events at 7 days and Radiation dosimetry at 3 hours. Started May 2024; status: completed.
02
Drugs
INR101
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06472531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472531.